447 related articles for article (PubMed ID: 27856614)
1. Next generation of small molecules in inflammatory bowel disease.
Olivera P; Danese S; Peyrin-Biroulet L
Gut; 2017 Feb; 66(2):199-209. PubMed ID: 27856614
[No Abstract] [Full Text] [Related]
2. Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease.
Boland BS; Vermeire S
Gastroenterol Clin North Am; 2017 Sep; 46(3):627-644. PubMed ID: 28838419
[TBL] [Abstract][Full Text] [Related]
3. Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.
Vuitton L; Koch S; Peyrin-Biroulet L
Curr Drug Targets; 2013 Nov; 14(12):1385-91. PubMed ID: 23627915
[TBL] [Abstract][Full Text] [Related]
4. Novel targets for inflammatory bowel disease therapeutics.
Löwenberg M; D'Haens G
Curr Gastroenterol Rep; 2013 Feb; 15(2):311. PubMed ID: 23314806
[TBL] [Abstract][Full Text] [Related]
5. The use of tofacitinib in the treatment of inflammatory bowel disease.
Weisshof R; Golan MA; Yvellez OV; Rubin DT
Immunotherapy; 2018 Aug; 10(10):837-849. PubMed ID: 29701124
[TBL] [Abstract][Full Text] [Related]
6. The use of Tofacitinib in the treatment of inflammatory bowel disease.
Nasonov EL; Abdulganieva DI; Fairushina IF
Ter Arkh; 2019 Mar; 91(2):101-108. PubMed ID: 31094180
[TBL] [Abstract][Full Text] [Related]
7. Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data.
Varyani F; Argyriou K; Phillips F; Tsakiridou E; Moran GW
Drug Des Devel Ther; 2019; 13():4091-4105. PubMed ID: 31819376
[TBL] [Abstract][Full Text] [Related]
8. TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES.
Teixeira FV; Damião AOMC; Kotze PG
Arq Gastroenterol; 2018; 55(2):198-200. PubMed ID: 30043874
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation Therapeutics for Inflammatory Bowel Disease.
Dulai PS; Sandborn WJ
Curr Gastroenterol Rep; 2016 Sep; 18(9):51. PubMed ID: 27461274
[TBL] [Abstract][Full Text] [Related]
10. Innovations in Oral Therapies for Inflammatory Bowel Disease.
Ma C; Battat R; Dulai PS; Parker CE; Sandborn WJ; Feagan BG; Jairath V
Drugs; 2019 Aug; 79(12):1321-1335. PubMed ID: 31317509
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.
Pantavou K; Yiallourou AI; Piovani D; Evripidou D; Danese S; Peyrin-Biroulet L; Bonovas S; Nikolopoulos GK
United European Gastroenterol J; 2019 Dec; 7(10):1285-1303. PubMed ID: 31839954
[TBL] [Abstract][Full Text] [Related]
12. Update on Janus kinase antagonists in inflammatory bowel disease.
Boland BS; Sandborn WJ; Chang JT
Gastroenterol Clin North Am; 2014 Sep; 43(3):603-17. PubMed ID: 25110261
[TBL] [Abstract][Full Text] [Related]
13. [Emerging Therapies: What Are Promising in the Near Future?].
Seo GS; Lee SH
Korean J Gastroenterol; 2018 Feb; 71(2):81-88. PubMed ID: 29471605
[TBL] [Abstract][Full Text] [Related]
14. Immune therapies in ulcerative colitis: are we beyond anti-TNF yet?
Raine T; Verstockt B; De Cruz P
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):794-796. PubMed ID: 32818453
[No Abstract] [Full Text] [Related]
15. Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature.
Peyrin-Biroulet L
Am J Gastroenterol; 2013 May; 108(5):859-60. PubMed ID: 23644972
[No Abstract] [Full Text] [Related]
16. [Pharmacology profile and clinical findings of tofacitinib citrate (Xeljanz® tablet 5 mg)].
Harada T; Nakamura H
Nihon Yakurigaku Zasshi; 2014 Sep; 144(3):133-41. PubMed ID: 25213614
[No Abstract] [Full Text] [Related]
17. First Oral Drug for Moderate-To-Severe Ulcerative Colitis.
Aschenbrenner DS
Am J Nurs; 2018 Sep; 118(9):22-23. PubMed ID: 30138199
[No Abstract] [Full Text] [Related]
18. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
[TBL] [Abstract][Full Text] [Related]
20. JAK inhibition in inflammatory bowel disease.
Olivera P; Danese S; Peyrin-Biroulet L
Expert Rev Clin Immunol; 2017 Jul; 13(7):693-703. PubMed ID: 28164724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
